Reuben College welcomes four new Visiting Fellows in January 2026

12 January 2026

Reuben College is delighted to have welcomed four new Visiting Fellows this month. These new members of our community bring leading expertise across a range of disciplines, including climate insights, entrepreneurship, medical technology, and health systems.

Meet our new Visiting Fellows

George Kamiya

A man of Asian descent with dark hair, glasses, and a stubbled beard. He is wearing glasses and a navy suit.

George Kamiya is Director of Climate Insights at the GSMA, the global industry association for mobile network operators. In this role, he provides strategic advice and analysis on energy, climate, and circular economy to support the mobile industry’s transition to net zero.

Prior to joining the GSMA in 2023, he led the International Energy Agency’s (IEA/OECD) analysis on the energy and climate impacts of digitalisation, as well as on modelling and policy analysis of other emerging topics including critical minerals for clean energy, cybersecurity and energy, and new mobility services. 

As an independent consultant, he has co-authored reports for the European Commission Joint Research Centre (JRC), International Energy Agency (IEA), and UN Trade and Development (UNCTAD).

George has a BSc in Marine Biology from the University of British Columbia and a Master of Resource Management from Simon Fraser University. As part of his graduate research, he led a large survey of new car buyers and modelled the short and long-run energy and emissions impacts of electric vehicles under different policy scenarios.

Andrew Thompson

Andrew Thompson, a smartly-dressed Caucasian man with short hair and glasses. He is smiling and turning away from his microphone.

Andrew Thompson is a Silicon Valley based entrepreneur and investor with a 30-year track record of successful technology-based innovation.  As a Founder and Chief-Executive he has personally negotiated three successful Merger & Acquisition transactions with Fortune 50 enterprises and completed NASDAQ Initial Public Offerings. 

He is co-founder and Managing Director of LifeSpeed, a business building platform that invests and advises early stage companies innovating at the intersection of technology and biology. The LifeSpeed portfolio includes TechMed and TechBio companies using new infrastructure to create a healthcare system for the 21st century that will complement our 20th century sickcare system.

Andrew Thompson grew up in the UK and holds Master’s degrees in Engineering (University of Cambridge), Education (Stanford University), and Business (Stanford University’s Graduate School of Business). He is also a named inventor on over 50 issued patents.

George Savage

George Savage, a smartly-dressed Caucasian man with dark features and hair

George Savage is a Silicon Valley-based entrepreneur and investor with a successful track-record of medical product innovation. As a founder, board member and C-level executive, he has taken revolutionary ideas through the full lifecycle from conception to funding, development, regulatory approval, commercialisation and exit. Dr Savage pioneered minimally-invasive surgery inside the heart, going from concept to FDA premarket approval in only three years. In 2014, he was named one of PharmaVoice’s 100 most inspiring people in the pharmaceutical industry.

From 2003 to 2020, Dr Savage was Co-Founder and Chief Medical Officer of Proteus Digital Health, where he won a landmark FDA approval for the first drug-device combination where the innovation was integrated silicon and software. From 2014-2025, he served on the board of the California Life Sciences Association.

Dr Savage is currently Co-Founder and CEO of Fulcrum Neuroscience, an AI digital twin company unravelling the causes of neurodegenerative diseases.

George Savage holds degrees in Biomedical Engineering (Boston University), Medicine (Tufts University) and Business (Stanford University). He is a named inventor on more than 50 issued patents and a Fellow of the American Institute of Medical and Biological Engineering.

Vivian Lee

Dr Vivian Lee, a smartly-dressed woman of Asian descent with shoulder-length black hair. She is speaking at a podium and smiling.

Vivian S. Lee, M.D., Ph.D., M.B.A, is President of Health Platforms at Verily Life Sciences, an Alphabet company whose mission is to apply digital solutions that enable people to enjoy healthier lives. She works closely with Verily’s clinical and engineering teams to develop products and platforms that support the successful transformation of health systems.

As a founding leader of Verily Health Platforms, Dr Lee’s role includes chairing the boards of Onduo and Granular, and leading the company’s COVID-19 employer and university product, Healthy at Work.

Dr Lee also serves as a Senior Lecturer at Harvard Medical School and Massachusetts General Hospital, and a Senior Fellow at the Institute for Healthcare Improvement. In 2019, she was ranked #11 among the Most Influential People in Healthcare. 

She holds a doctorate in medical engineering from Oxford University as a Rhodes Scholar, an M.D. with honours from Harvard Medical School, an Executive MBA from NYU Stern, and is a magna cum laude graduate of Harvard-Radcliffe Colleges. She is a member of the National Academy of Medicine and a former Dean, SVP and CEO of University of Utah Health.